Abstract
Objective
To assess the oncological outcomes of radical cystectomy (RC) and adjuvant chemotherapy to treat muscle-invasive bladder cancer (MIBC) with a micropapillary component (MPC), and to compare outcomes with those from pure urothelial carcinoma (PUC).
Materials and methods
A retrospective review of clinicopathological and follow-up data was performed for all patients treated by RC and adjuvant platinum-based chemotherapy for advanced MIBC in three tertiary reference centers between 1999 and 2012. Uni- and multivariate Cox’s regression analyses evaluated the association of the presence of MPC with disease recurrence and cancer-specific mortality.
Results
Two hundred and thirty-five (88 %) PUC and 31 (12 %) MPC cases were included. Median age was 65 (39–83) years in the PUC group and 62 (45–80) years in the MPC group. Median survival was 29 months in the MPC versus 31 months in the PUC group. No significant difference was observed between the groups regarding main clinical and pathological characteristics. The median number of treatment cycles administered was 6 (3–8) in the PUC versus 5 (3–8) in the MPC group (p = 0.45). Five-year disease-free recurrence and cancer-specific survival (CSS) rates were 15 and 24 %, respectively, in the MPC versus 42 and 47 %, respectively, in the PUC group (p = 0.007 and 0.058). In multivariate analyses, ASA score, soft tissue surgical margins, and MPC were associated with disease recurrence (p = 0.022, 0.001, and 0.015, respectively). We found no association between MPC and cancer-specific mortality (univariate, p = 0.06).
Conclusion
MPC was associated with higher recurrence rates after RC and platinum-based adjuvant chemotherapy than that with pure urothelial tumors.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11
Howlader NNA, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W et al (2009) SEER cancer statistics review, 1975–2009 (vintage 2009 populations). National Cancer Institute, Bethesda
Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA et al (2012) ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63:45–57
Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF et al (2013) ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 63:58–66
Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967–3972
Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y et al (2012) Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 187:457–462
Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG et al (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12:6663–6676
Xylinas E, Cha EK, Sun M, Rnk M, Trinh QD, Novara G et al (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107:1826–1832
(2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol, 48: 189–201
Amin MB, Ro JY, El-Sharkawy T, Lee KM, Troncosco P, Silva EG et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18:1224–1232
Vourganti S, Harbin A, Singer EA, Schuch B, Metwalli AR, Agarwal PK (2013) Low grade micropapillary urothelial carcinoma, does it exist?—analysis of management and outcomes from the surveillance, epidemiology and end results (SEER) database. J Cancer 4:336–342
Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A, Hernandez-Hernandez DM (2005) Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol 9:1–5
Maranchie JK, Bouyounes BT, Zhang PL, O’Donnell MA, Summerhayes IC, DeWolf WC et al (2000) Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 163:748–751
Oh YL, Kim KR (2000) Micropapillary variant of transitional cell carcinoma of the ureter. Pathol Int 50:52–56
Samaratunga H, Khoo K (2004) Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology 45:55–64
Vang R, Abrams J (2000) A micropapillary variant of transitional cell carcinoma arising in the ureter. Arch Pathol Lab Med 124:1347–1348
Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H et al (2013) Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol 32:110–116
Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarell RF, Thapa P et al (2012) Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol 30:801–806
Xylinas E, Rink M, Robinson BD, Lotany Y, Babjuk M, Brisuda A et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–1897
Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P et al (2007) Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110:62–67
Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A (2009) Micropapillary bladder cancer: a review of leon berard cancer center experience. BMC Urol 9:5
Lopez-Beltran A, Montironi R, Blanca A, Cheng L (2010) Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol 41:1159–1164
Masson-Lecomte A, Colin P, Bozzini G, Nison L, de La Taille A, Comperat E et al (2014) Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 32:531–537
Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M, Patino M, Ruiz E (2009) Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol 13:151–157
Warth A, Muley T, Meister M, Stenzinger A, Thomas A, Schirmacher P et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446
Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH et al (2013) Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int 111:E325–E330
Siefker-Radtke AO, Dinney CP, Shen Y, Dl Williams, Kamat AM, Grossaman HB et al (2013) A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119:540–547
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751–757
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M et al (2013) Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 111:E30–E36
Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE et al (2010) Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 34:1367–1376
Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chire et al (2012) Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 25:1574–1583
Shah RB, Montgomery JS, Montie JE, Kunju LP (2013) Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 3:2650–2655
Comperat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I et al (2010) Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 42:650–654
Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Fabaa O, Villavicencio H (2010) The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 17:5370–5376
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical standard
The Ethics Committee of the Assistance Publique-Hôpitaux de Paris (AP-HP) (i.e., IRB approval) approved the study, and the principles of the Declaration of Helsinki were respected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masson-Lecomte, A., Xylinas, E., Bouquot, M. et al. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J Urol 33, 1087–1093 (2015). https://doi.org/10.1007/s00345-014-1387-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-014-1387-1